Pfizer Inc. (PFE)
After hours:
| Previous close | 25.26 |
| Open | 25.33 |
| Bid | 25.41 x 4000 |
| Ask | 25.46 x 2900 |
| Day's range | 25.20 - 25.54 |
| 52-week range | 25.20 - 40.37 |
| Volume | |
| Avg. volume | 42,220,991 |
| Market cap | 143.829B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | 68.65 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.68 (6.65%) |
| Ex-dividend date | 09 May 2024 |
| 1y target est | N/A |
- Investor's Business Daily
A Big Week For The Stock Market: Apple, Amazon, Big Pharma And The Fed
Stock market investors brace for a big week of earnings and econ as Apple, Amazon, Big Pharma and The Fed all line up to deliver news.
- Benzinga
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
Friday, the FDA approved Pfizer Inc’s (NYSE:PFE) Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var capsid. Beqvez is a one-time treatment designed to enable hemophilia B patients to produce FIX themselves
- Investor's Business Daily
Pfizer Wins FDA Approval For $3.5 Million Gene Therapy, Rivaling CSL, Uniqure
The FDA approved Pfizer's hemophilia gene therapy on Friday. But Pfizer stock only inched ahead on the approval early Friday.
